MedTrace Logo

A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

NCT02021500 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-11-01

No results posted yet for this study

Summary

A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.

Conditions

Interventions

DRUG

ABI-007

No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Victoria Manax, MD · Celgene

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-02
Primary Completion
2015-04-16
Completion
2015-04-16

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • France
  • Germany
  • Italy
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02021500 on ClinicalTrials.gov